EHA 2023 | Long-term findings from MCL0208: lenalidomide maintenance post autoSCT in MCL
Marco Ladetto, MD, Hospital SS. Antonio e Biagio and Cesare Arrigo, Alessandria, Italy, discusses the long-term results of the Phase III MCL0208 trial (NCT02354313). The study evaluated lenalidomide maintenance therapy after autologous stem cell transplantation (autoSCT) for mantle cell lymphoma (MCL). The two-year lenalidomide therapy demonstrated an early benefit to progression-free survival (PFS) which was not maintained once lenalidomide was interrupted, thus emphasizing the importance of long-term maintenance therapy post autoSCT. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy, participation to advisory boards, invitation to scientific meetings, institutional research support and contracts with: AbbVie, Acerta, Amgen, ADC Therapeutics, BeiGene, Celgene/BMS, Eusapharma, GSKI, Gentili, Gilead/Kite, Lilly, Novartis, Incyte J&J, Jazz, Regeneron, Roche, Sandoz. Non-financial interests: PI or strategic investigator in studies supported by: Celgene, J&J, BeiGene, ADC Therapeutics
